Being Early On An Early Asset: Trillium May Be A Diamond In The Rough Immunotherapy Stock
October 29, 2014 at 10:59 AM EDT
Trillium Therapeutics is an immuno-oncology company developing novel cancer therapeutics. Their primary target, the CD47 antigen, is generating significant attention from industry and academia alike.
